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Abstract
It has been shown that high vitamin A intake is associated with bone fragility and fractures in both animals and humans.
However, the mechanism by which vitamin A affects bones is unclear. In the present study, the direct effects of retinoic acid
(RA) on human and murine osteoclastogenesis were evaluated using cultured peripheral blood CD14
+ monocytes and
RAW264.7cells.Both theactivityoftheosteoclastmarkertartrateresistantacidphosphatase(TRAP) inculture supernatantand
the expression of the genes involved in osteoclast differentiation together with bone resorption were measured. To our
knowledge, this is the first time that the effects of RA on human osteoclast progenitors and mature osteoclasts have been
studied in vitro. RA stimulated proliferation of osteoclast progenitors both from humans and mice. In contrast, RA inhibited
differentiation of the receptor activator of nuclear factor kB ligand (RANKL)-induced osteoclastogenesis of human and murine
osteoclast progenitors via retinoic acid receptors (RARs). We also show that the mRNA levels of receptor activator of nuclear
factor kB (RANK), the key initiating factor and osteoclast associated receptor for RANKL, were potently suppressed by RA in
osteoclast progenitors. More importantly, RA abolished the RANK protein in osteoclast progenitors. This inhibition could be
partially reversed by a RAR pan-antagonist. Furthermore, RA treatment suppressed the expression of the transcription factor
nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) and increased the expression of interferon regulatory factor-8 (IRF-8)
in osteoclast progenitors via RARs. Also, RA demonstrated differential effects depending on the material supporting the cell
culture. RA did not affect TRAP activity in the culture supernatant in the bone slice culture system, but inhibited the release of
TRAP activity if cells were cultured on plastic. In conclusion, our results suggest that retinoic acid increases proliferation of
human osteoclast progenitors and that it inhibits RANK-stimulated osteoclast differentiation by suppressing RANK.
Citation: Hu L, Lind T, Sundqvist A, Jacobson A, Melhus H (2010) Retinoic Acid Increases Proliferation of Human Osteoclast Progenitors and Inhibits RANKL-
Stimulated Osteoclast Differentiation by Suppressing RANK. PLoS ONE 5(10): e13305. doi:10.1371/journal.pone.0013305
Editor: Michael Polymenis, Texas A&M University, United States of America
Received April 16, 2010; Accepted September 15, 2010; Published October 11, 2010
Copyright:  2010 Hu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by The Swedish Research Council (HM and GA) and The Swedish Society of Medicine (TL). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Lijuan.Hu@medsci.uu.se
. These authors contributed equally to this work.
¤ Current address: Ludwig Institute for Cancer Research, Uppsala University, Biomedical Centre, Uppsala, Sweden
Introduction
Vitamin A, including its active metabolite retinoic acid (RA), is
required for normal growth and is a potent regulator of physiological
activities such as vision, reproduction, growth and development in
vertebrates [1]. In particular its roles in the skeletal development and
metabolism have been recognized since a long time [2]. Hypervita-
minosis A causes accelerated thinning of long bones, bone fragility and
spontaneous fractures in animal experiments. Furthermore, high
intake of dietary vitamin A and serum retinol levels have been
associated with increased risk of hip fractures in humans [3,4,5,6].
Retinoic acid is suggested to mediate much of the physiological effects
of retinol via binding to retinoic acid receptors (RARa, b, c)w h i c h
form heterodimers with retinoic X receptors (RXRa, b, c)[ 7 ] .T h e
RAR/RXR heterodimers function as transcription factors, activating
specific RA response elements (RAREs) for transcriptional regulation
of the target genes [7,8].
Osteoclasts are multinucleated, TRAP positive and bone
resorbing giant cells derived from hematopoietic cells of the
myeloid lineage. Macrophage colony-stimulating factor (M-CSF,
also termed CSF1) and RANKL (Tnfsf11) are essential molecules
for the differentiation of osteoclasts, and are abundantly expressed
in stromal cells/osteoblasts [9,10,11]. M-CSF supports prolifera-
tion and survival of osteoclast precursors and increases the
expression of the receptor for RANKL, i.e. RANK (Tnfrsf11a)
[12,13]. The interaction between RANKL and RANK is critical
for osteoclast differentiation and activation of mature osteoclasts
[9,10,11]. Mice deficient in M-CSF, RANKL, or RANK have
defect osteoclasts and develop osteopetrosis [14,15,16,17]. Stromal
cells/osteoblasts release osteoprotegerin (OPG) which is a soluble
decoy receptor for RANKL and functions as a potent inhibitor of
osteoclastogenesis. The rate of osteoclastogenesis and bone
resorption under physiological conditions of bone homeostasis is
correlated to the ratio of RANKL to OPG. A targeted deletion of
OPG in mice often results in multiple fractures, numerous
osteoclasts, and decreased trabecular bone volume [18].
RANKL signals through RANK in osteoclast precursors and
sequentially activates nuclear factor kappa-light-chain-enhancer of
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(MAPKs). RANK signaling additionally leads to induction of c-Fos,
which is a prerequisite condition for the induction of NFATc1, a
master transcription factor for osteoclastogenesis. MafB and IRF-8
are transcription factors that are abundantly expressed in osteoclast
precursors and are thought to be important negative regulators of
osteoclast differentiation [19,20]. MafB and IRF-8 suppress the
activity of NFATc1 and thereby reduce the expression of NFATc1
target genes. When RANK is activated by RANKL, it sends signals
into TNF receptor-associated factor molecules (TRAFs), leading to
up-regulationofthedownstreammoleculessuch asc-Fosanddown-
regulation of MafB and IFR-8 which regulate NFATc1 activity and
its auto-amplification, resulting in the activation, survival and
differentiation of osteoclasts.
The effects of retinoids on osteoclasts have been examined in vitro,
but findings vary between different systems. Studies of organ cultured
bone consistently show increased resorption. Similarly, the over-
whelming amount of data in mature chicken and rabbit osteoclasts
show increased activity by RA [21,22,23,24,25,26]. In contrast, the
majority of data show that RA inhibits osteoclast differentiation when
cell sfr ommu r inebonema r r owhavebeenuse d.I nvivo studies suggest
that RA has opposite affects on trabecular and cortical bone [25].
The effects on human osteoclast progenitors have not been studied.
SinceRA haseffects on both human osteoblasts [27] and stromal cells
[28], a pure cell culture system is required to evaluate the direct
molecular mechanisms. In the present study, we therefore investi-
gated the effects of RA on osteoclast progenitors from purified
peripheral blood CD14
+ monocytes. The effects of retinoids may be
influenced not only by the culture system and sources of osteoclasts,
but also by species [21,25,29,30,31,32,33]. For this reason we studied
the effects of RA on both human and murine osteoclast progenitors
and on RANKL-induced maturation of these cells, cultured on bone
as well as plastic substrates.
Materials and Methods
Materials
Recombinant human M-CSF and RANKL were obtained from
Nordic BioSite AB (Sweden). Bone slices and Cross Laps ELISA
kits were from Immunodiagnostic Systems Nordic (Denmark). All-
trans-retinoic acid (RA) was purchased from Sigma Aldrich,
Sweden and was dissolved in 95% ethanol in the dark room
under the flow of nitrogen. The stock solution (0.5 mg/ml or
1.66 mM) was stored at 270uC and shielded from light until use.
The RAR pan-antagonist AGN194310 (AGN), which was
dissolved in dimethyl sulfoxide (DMSO), was kindly provided by
Dr. Chandraratna, Allergan Inc, Irvine, CA USA.
Osteoclast formation in RAW264.7 cell culture
RAW264.7 cells (from ATCC) were cultured as described
previously [34]. In brief, the cells were seeded in a 96-well plate
either on plastic or on bone slices at a density of 1.5610
3 cells per
well. Cells were cultured for 6 or 7 days in the control medium (a-
MEM containing 10% FBS, 2 mM L-glutamine and 1%
penicillin) or in the control medium in the presence of 100 ng/
ml recombinant human RANKL with or without RA and AGN.
Osteoclast formation in the human CD14
+ cell culture
Isolation and differentiation of CD14
+ monocytes were carried
out as described previously [35]. In brief, buffy coat blood was
obtained from anonymous healthy donors at Uppsala University
Hospital. Uppsala University Hospital ethics committee approved
the study and waived the need for consent from donors. The
peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Paque Plus (GE healthcare, Sweden) density gradient
centrifugation according to the manufacturer’s instruction. The
PBMCs were re-suspended in cold PBS containing 0.5% BSA and
2 mM EDTA. The human CD14
+ monocytes were isolated using
the positive immunomagnetic selection based on the cell surface
markers by human CD14
+ beads from Miltenyi Biotec (Germany).
Human CD14
+ cells were seeded in the control medium with
25 ng/ml M-CSF for 3 days. By the third day, the cells were
detached by incubation with trypsin at 37uC for 20 minutes and
removed by a scraper. Then the cells were seeded in a 96-well
plate at a density of 1.5610
5 cells per well on bone slices or 5610
4
cells on plastic with the control medium supplemented with M-
CSF and RANKL each at 25 ng/ml as previously described [35].
For the osteoclast progenitor experiment, 4 nM of RA and 8 nM
of the AGN were added on day 0 and incubated for 3 days or 2
weeks. For the mature osteoclast experiment RA was added on
day 14 for 2, 8 or 12 days. The culture medium was replaced every
second day during the experiment.
The proliferation of osteoclast progenitors
RAW264.7 cells were cultured in the absence or presence of
100 ng/ml recombinant human RANKL with or without RA in a
96-well plate for 6 days. Human CD14
+ cells were seeded in the
control medium with 25 ng/ml of M-CSF in the absence or
presence of 25 ng/ml of RANKL with or without 4 nM of RA in a
96-well plate or 12-well plate for 14 days. The cell proliferation
was measured with the MTT kit (Sigma Aldrich, Sweden) in a 96-
well plate or by cell number counting in a 12-well plate with
NucleoCounterTM (Chemometec, Allerød, Denmark) following
the manufacturer’s instructions.
Determination of Osteoclast Formation
Osteoclasts were identified by measuring TRAP activity in the
c u l t u r em e d i u m .Am o r et h a n3 - f o l di n c r e a s eo ft h eT R A Pa c t i v i t y
compared with control indicates the formation of osteoclasts. The
TRAP activity measurement was carried out using an adapted Sigma
protocol as described [36]. Briefly, medium was added to the ELISA
plates containing 0.1 M acetate (pH 5.2),0.15 M potassium chloride,
0.1% triton X-100, 1 mMascorbicacid Na-salt, 0.1 mM ammonium
ferrious sulfate hexahydrate, 10 mM phosphatase substrate p-
nitrophenyl phosphate (PNPP) and 10 mM Na-tartrate acid buffer.
The plate was incubated at 37uC for 30 minutes. The reaction was
stopped with the addition of 0.3 N NaOH and absorbance was
measured at 405 nm. TRAP catalyzes the conversion of PNPP to p-
nitrophenol (PNP), giving a maximal absorbance at 405 nm, which
corresponds to the TRAP activity in the sample. Also, TRAP
+ cells
containing 3 or more nuclei were considered as osteoclasts. The
TRAP staining was carried out using the Acid Phosphatase,
Leukocyte (TRAP) Kit (Sigma-Aldrich Sweden).
Resorption assay
The release of C-terminal telopeptide of type I collagen (CTX)
from mineralized bone slices was determined using CrossLaps for
Culture kit (Nordic Bioscience Diagnostics, Denmark) according to
the manufacturer’s instructions.
RNA isolation and gene expression measured by Real-
Time PCR
Human CD14
+ cells were seeded in a 96-well plate at a density
of 1.5610
5 cells or 5610
4 cells per well on bone slices or plastic,
respectively, with the control medium supplemented with M-CSF
and RANKL each at 25 ng/ml as previously described [35]. For
the effects of RA in the osteoclast progenitor experiment, 4 nM of
Osteoclast and Retinoic Acid
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third day the cells were washed twice with PBS and lysed in RLT
lysis buffer (Qiagen). Total RNA was isolated using the RNeasy
Kit (Qiagen). A one-step reaction was performed in a GeneAmp
PCR System 9700 (Applied Biosystems) to reversely transcribe
about 50 ng of total RNA into cDNA with the High Capacity
cDNA reverse transcription kit (Applied Biosystems). The cDNA
was then amplified using the TaqManH real-time PCR on ABI
PRISMH 7000 Sequence Detection Systems (Applied Biosystems).
All reactions were performed in 96-well plates with a final volume
of 25 ml per well. Cycling conditions were 2 minutes at 50uC
followed by 10 minutes at 95uC to activate the Taq DNA
Polymerase, and 40 cycles of 15 seconds at 95uC, and finally 60
seconds at 60uC. Quantitative PCR was performed using
inventoried TaqManH Gene Expression Assays for CD14, RANK,
IRF-8, NFATc1 and cathepsin K mRNA measurements. The
target gene expressions were compared with that of b-actin to
obtain the relative mRNA expression.
Western blot analysis
Human CD14
+ cells were seeded at a density of 1610
5 cells/cm
2
in a 24-well plate and incubated in the presence of 25 ng/ml of M-
CSF and 25 ng/mlof RANKL with or without 4 nM of RA or 8 nM
of AGN for 3 days. Cells were lysed and proteins were separated on
an 8% SDS-PAGE gel and blotted onto a nitrocellulose membrane
(GE healthcare, Sweden). The membrane was rinsed and blocked
with 5% BSA in TBS/0.05% Tween-20 and incubated with RANK
and b-actin antibodies (Santa Cruz biotechnology, CA.USA) for
o v e r n i g h ta t4 uC, followed by incubation with a horseradish-
conjugated secondary antibody for 1 hour. The protein bands were
visualized with an ECL detection system (GE healthcare, Sweden).
Results
RA inhibits osteoclast differentiation
Secreted TRAP activity, a marker of the osteoclast resorption
capacity [37], in the medium of murine RAW264.7 cells was
significantly increased 3 to 5 times compared to cells not receiving
RANKL on plastic (Figure 1A, B). TRAP staining of these cells
revealed an abundance of osteoclasts with more than 3 nuclei both
on plastic and bone slices (Figure 1C, expanded figure in Figure
S2). However, no functional osteoclasts were formed, measured as
CTX fragment generation, when the RAW264.7 cells were
cultured with RANKL on bone slices (data not shown). RA
inhibited the RANKL-induced osteoclast differentiation when it
was added to the RAW 264.7 cell cultures on plastic (Figure 1A-
C). RA at a concentration as low as 0.4 nM was sufficient to
inhibit TRAP release in RAW 264.7 cells (Figure 1A). No
multiple-nuclear TRAP positive cells were found in the presence of
4 nM RA (Figure 1C). The RAR pan-antagonist (AGN) partially
reversed the inhibition of osteoclastic TRAP release and multi-
nuclear TRAP-positive osteoclast formation by RA (Figure 1B, C).
To test the effect of RA on human cells we used a standard,
validated culture system for human osteoclastogenesis involving
culturing peripheral blood purified CD14
+ cells with M-CSF and
RANKL for 10–14 days [35]. In these cultures TRAP-release was
increased 42- and 13-fold compared with the cells not receiving
RANKL seeded on plastic or bone slices, respectively (Figure 1E).
Importantly, these cells were functional osteoclasts as the bone
resorption activity was highly induced by RANKL, measured as
CTX fragment generation, when cells were cultured on bone slices
(Figure 1G). RA inhibited the RANKL-induced osteoclast
differentiation when it was added to human CD14
+ cells both
on plastic and bone slices (Figure 1D–F). The inhibition can even
be observed at a concentration as low as 0.04 nM of RA on
human CD14
+ cells (Figure 1D and Figure S1). RA at 4 nM in the
human CD14
+ cell culture in the presence of M-CSF and RANKL
almost completely abolished the formation of multi-nuclear
TRAP-positive cells together with a near total elimination of
TRAP- and CTX-release (Figure 1D–G, Figure 1F was expanded
in Figure S2). Osteoclast formation, TRAP- and CTX-release
were largely restored in the presence of the RAR-pan-antagonist
(Figure 1E–G). These results were consistent irrespective of the
carrier for the cell culture, i.e. plastic or bone.
RA increases osteoclast progenitor proliferation
An MTT cell proliferation assay revealed that 4 nM of RA
stimulated proliferation of both murine and human osteoclast
progenitors (p,0.001, Figure 2A, B). Cell number count also
indicated a similar proliferation pattern in the human CD14
+ cells
treated with 4 nM RA (Figure 2C). Also, initiating osteoclast
differentiation by the addition of RANKL did not reduce the
proliferation induction capacity of RA. RANKL alone slightly
decreased proliferation in RAW 264.7 cells (p,0.05) but had no
effect on the human cells. We observed similar proliferation
patterns in both murine and human osteoclast progenitors in the
MTT assay, when the cells were treated with 400 nM of RA (data
no shown). No apparent toxic effect was detected after RA
treatment in doses up to 1610
26 M in RAW264.7 and human
CD14
+ cells (data not shown).
RA does not inhibit mature osteoclast function
The normal physiological level of circulating RA in humans is
estimated to be #10 nM and effective pharmacological concen-
tration is .100 nM [38,39]. The highest concentration of RA
measured in human plasma upon RA treatment has been shown
to be approximately 400 nM [40]. Here when mature murine or
human osteoclasts were treated with RA at the highest
pharmacological dose of 400 nM for 2 days, no difference was
observed in terms of released TRAP activity or cellular TRAP
staining (Figure 3A–D). To directly test if these levels of RA
affected the ability of human osteoclasts to degrade bones, we
measured CTX fragment released into culture media from
osteoclasts cultured on bone slices. This revealed that, similar to
released TRAP activity, 400 nM of RA for 2 days did not affect
CTX fragment release (Figure 3E). In fact human osteoclasts
cultured on bone slices, with or without 400 nM RA, show similar
stable release of TRAP activity and cellular TRAP staining over a
12-day period (Figure 3D, F). However, if cultured on plastic,
osteoclasts receiving 400 nM RA release less TRAP activity at
treatment day 4, and by day 8 it is essentially at levels similar to
precursor cells not receiving RANKL, although cellular TRAP
staining was unaltered (Figure 3D, G).
RA suppresses RANK expression
The potent inhibitory effect of RA on osteoclast formation
suggests that it affects early signaling. Here, as signaling through
RANK in preosteoclasts is the key initial osteoclast differentiation
factor, we investigated how RA affects RANK expression. Real-
time PCR analysis showed that 4 nM of RA potently reduced
RANK mRNA expression in differentiation cultures on bone slices
on day 3 although the effect was less obvious if cells were cultured
on plastic (Figure 4A, B). More importantly, 4 nM of RA almost
completely abolished RANK protein production in human
osteoclast progenitors (Figure 4C). RANK mRNA expression
was fully reversed by 8 nM of the RAR pan-antagonist and
protein expression was partially reversed (Figure 4A–C).
Osteoclast and Retinoic Acid
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Finally, we tested how RA affects a set of osteoclast-associated
genes during early (day 3) osteoclast differentiation. The progenitor
marker CD14 and the negative osteoclastogenic regulator IFR-8
expression werereduced by RANKL(Figure5A–D). Thisreduction
was prevented by additionof 4 nM of RA. However, whereas 8 nM
of the RAR pan-antagonist fully reversed this effect in osteoclast
cultured on plastic (Figure 5B, D), no effect was observed on bone
cultures (Figure 5A, C). The expression of the positive markers for
osteoclasts, NFATc1 and cathepsin K, were induced at a higher
Figure 1. RA inhibits differentiation of osteoclast progenitors. TRAP activity in medium in RAW264.7 cells incubated with RANKL (RL, 100 ng/
ml) with various concentrations of RA (A), or in the presence or absence of 4 nM of RA or 8 nM of RAR pan-antagonist (AGN) (B, C) on bone slices or
plastic for 7 days was measured as described in materials and methods. Human CD14
+ blood monocytes were incubated with M-CSF (M, 25 ng/ml),
RANKL (RL, 25 ng/ml) and various concentrations of RA (D), or in the presence or absence of 4 nM RA or 8 nM AGN on bone slices for 14 days or on
plastic for 10 days (E–G). Release of TRAP activity in the culture medium was determined using an adapted Sigma protocol (A, B, D, E). The TRAP
staining was carried out using the Acid Phosphatase Leukocyte (TRAP) kit (C, F). CTX was determined by CrossLaps ELISA kit (G). Each data point
represents the average 6 SD of triplicate wells. Similar results were obtained in more than three independent experiments. NS means non-significant
difference. A, D, compared with RL group. * P,0.05, *** P,0.001.
doi:10.1371/journal.pone.0013305.g001
Figure 2. RA increases proliferation of the osteoclast progenitors. RAW264.7 cells (A) were incubated in a 96-well plate in the presence or
absence of RANKL (RL) and 4 nM of RA for 6 days. Human CD14
+ cells were incubated in a 96-well plate (B) or 12-well plate (C) in the absence
or presence of M-CSF (M), RANKL (RL), and 4 nM of RA for 14 days. Cell proliferation was determined by an MTT based cell growth determination kit
or cell number counting with NucleoCounter. Each data point represents the average 6 SD of triplicate wells. Similar results were obtained in more
than three independent experiments. NS denotes non-significant difference. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0013305.g002
Osteoclast and Retinoic Acid
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The expression of both genes was reduced by RA via RARs
although the result from NFATc1 was less distinct.
Discussion
This study showed that RA at doses as low as 4 nM significantly
repressed RANKL-induced differentiation of osteoclasts from
human and murine precursor cells in vitro. Our finding is in
agreement with previous studies that suggest direct inhibitory
effects of RA on osteoclast formation in vitro from various mouse
tissue sources [25,32,41,42]. The negative effect on osteoclast
differentiation by RA could partly be rescued by a RAR pan-
antagonist. Therefore, it is reasonable to conclude that the
inhibition of osteoclast formation was, at least in part, mediated via
RARs. In order to confirm that the effect of RA on osteoclasto-
genesis in RAW264.7 cells and human CD14
+ cells were not due
to toxic effects of the reagents, cell growth determination assay was
performed. RA-induced inhibition of osteoclast formation oc-
curred with no morphological signs of cytotoxicity or decreased
cell numbers in either the RAW264.7 or human CD14
+ cells. On
the contrary, cell proliferation was observed in the presence of RA.
Moreover, the osteoclast differentiation inducer RANKL did not
alter the increased proliferation levels obtained with RA. These
findings are in agreement with previous studies that have
demonstrated enhancement of proliferation capacity of RA in
Figure 3. RA does not inhibit mature osteoclast function. RAW264.7 cells were incubated with RANKL on bone slices or plastic for 5 days
followed by incubation in 400 nM of RA for another 2 days (A–B). Human CD14
+ cells were incubated on bone slices or plastic with M-CSF (M) and
RANKL (RL) for 14 days or 10 days. The cells were then incubated in 400 nM of RA for another 2 days (D–E), or 12 days (D, F) on bone slices or on
plastic for 2 days (C, D) or 8 days (G). The CTX measurements (E), secretion of TRAP activity (A, C, F, G) and the TRAP staining (B, D) were carried out as
explained in Figure 1.
doi:10.1371/journal.pone.0013305.g003
Figure 4. RA inhibits RANK expression in human osteoclast progenitors via RARs. Human CD14
+ cells were incubated with or without M-
CSF, RANKL, RA (4 nM) or AGN (8 nM) on bone slices (B) or plastic (A) for 3 days. mRNA levels were measured using real-time PCR and were
normalized relative to the expression of b-actin. (C) Whole cell lysates were subjected to SDS-PAGE and immunoblotted with RANK and b-actin
antibodies. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0013305.g004
Osteoclast and Retinoic Acid
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+ cells were treated on bone slices (A, C, E, G) or plastic (B, D, F, H) as
described in Figure 4. mRNA levels were measured using real-time PCR and were normalized relative to the expression of b-actin. * P,0.05, **
P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0013305.g005
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tumors from bone and mouse skin epidermal cells [29,43,44]. By
contrast, a recent study was unable to show increased proliferation
of mouse bone marrow macrophages (BMM) with RA [32]. This
discrepancy may be due to the fact that their protocol involved
shorter culture periods and higher concentrations of RA. The
explanation could also be that there are differences between
human CD14
+ cells and mouse BMM.
Doses of RA (400 nM) for 2 days in culture did not affect the
function of mature murine osteoclasts or mature human
osteoclasts measured as release of TRAP activity compared to
untreated controls. Importantly, 400 nM of RA over 2 days did
not affect the bone resorbing activity of mature human osteoclasts
as measured by unaltered CTX release. In mature human
osteoclasts cultured on bone slices, no difference in released
TRAP activity was observed compared with mature human
osteoclast controls, even when the cells were treated with 400 nM
of RA for 12 days. However, in the plastic culture system an
inhibition was observed after 4 days with RA treatment.
Therefore, different results may be obtained depending on the
culture system used and the length of incubation. This is a novel
finding. We believe that osteoclasts cultured on bone slices should
reflect the real physiological situation more closely, but the
different results might be due to the interactions between the
osteoclasts and the micro-environment on bone slices. For
instance, an indirect effect via osteoblasts on osteoclasts cannot
be excluded since we have previously shown that RA markedly
increases the RANKL/OPG ratio in human osteoblasts, which
would lead to a stimulation of bone resorption [27]. That mature
osteoclasts are activated in the presence of high RA concentrations
is in line with the observations of increased bone resorption during
hypervitaminosis A and increased bone degradation in organ
cultures by retinoids [24,45]. Also, a few studies using avian and
rabbit osteoclasts have shown that RA or retinol could enhance the
resorption activity of mature osteoclasts in vitro [21,22,26]. Our
finding that RA exhibits major effects on precursors but little effect
on mature osteoclasts is consistent with the recent observation by
Conaway et al [32] that an inhibitory effect of RA on osteoclast
differentiation in cultured bone marrow macrophages is seen when
RA is added at a very early stage but the effect is gradually lost
when RA is added later [32].
Our study revealed small but distinct differences in gene
expression patterns of the CD14
+ human osteoclast progenitor
cells depending on the carriers for the cell culture. An
explanation for this may be provided by the fact that we
noticed, upon seeding of osteoclast progenitors, that fewer cells
attached to bone slices compared to plastic surfaces, eventhough
a cell density three times that of plastic cultures was seeded on
bone slices. That’s why we observed a delay in osteoclast
formation by 5 to 6 days with the bone slices. Thus, we speculate
that the lower initial cell density on bone slices in this study may
perhaps cause a slower osteoclast differentiation rate compared
to the cultures on plastic. An apparent delay would fit our
o b s e r v a t i o nt h a tc u l t u r e so np l a stic show a clearer trend towards
induction of the positive regulators of osteoclastogenesis,
NFATc1 and cathepsin K, compared to cultures on the bone.
NFATc1 is believed to be a master transcription factor for
murine osteoclastogenesis [46,47]. Here we noticed that the
induction pattern of cathepsin K expression by human
osteoclasts appears earlier compared to NFATc1, which is in
agreement with earlier observations in human osteoclast cells
[48]. Furthermore RANK mRNA expression appears to be
transiently increased by RANKL in mouse BMM cultures on
plastic with a peak induction after 2 days followed by reversal to
almost control levels after 3 days [32]. Here, cultures on both
bone and plastic present no increase in RANK mRNA
expression after 3 days of RANKL treatment. However,
importantly RA treatment induced a clear RAR-dependent
r e d u c t i o no fR A N Km R N Ai nc u l t u r e so nt h eb o n e .T h et r e n d
was also true for the cultures on plastic although the RA-induced
reduction of RANK transcripts did not reach significance.
RANK is the key factor present on precursor cells essential for
initiating osteoclast differentiation. Here we show that 4 nM of
RA almost completely abolished the RANK protein produced
by precursor cells and that this was, at least in part, reversible
with a RAR pan-antagonist. It has previously been shown that
TGF-b, Toll-like receptor agonists and IFN-c reduce RANK
protein expression on human osteoclast precursors. Our study
shows that also RA is a potent inhibitor of RANK protein
expression in these cells [49,50].
IRF-8 has been shown to be a negative regulator of
osteoclastogenesis. Mice deficient in IFR-8 show severe osteo-
porosis, owing to increased numbers of osteoclasts [20]. In
human CD14
+ cells, RANKL overcomes this negative regula-
tion and stimulates osteoclast formation by decreasing expres-
sion of IRF-8 in cells cultured on both bone slices and plastic. In
the present study, RA antagonized the RANKL-induced
reduction of IRF-8, which is in line with the finding that RA
inhibits the expression of the RANKL receptor and thereby
makes precursor cells refractory to the effects of RANKL. IFR-8
is thought to function as a negative regulator of osteoclast
formation by binding NFATc1 and preventing transactivation of
NFATc1. This possibly explains why RA also suppressed
NFATc1 in our cultures. We did not detect any effect of RA
on the expression of MafB, another repressor of osteoclastogen-
esis, in our primary human cultures as was recently shown for
murine cells [32].
In conclusion, our results suggest that the major impact of RA
on osteoclast biology in vitro is its substantial effects on precursor
cells. RA increases osteoclast precursor proliferation and potently
inhibits RANKL-stimulated osteoclast differentiation in both
human and murine cells. An RA concentration as low as 4 nM
suppresses RANK mRNA and protein expression in human
osteoclast progenitors. The strong capacity of RA to suppress the
early key osteoclastogenesis factor, the RANK protein, may
explain its potent ability to inhibit osteoclastogenesis.
Supporting Information
Figure S1 RA inhibits differentiation of osteoclast progenitor
human CD14+ cells. Number of multinucleated TRAP-positive
cells in human CD14+ cells incubated with M-CSF (M, 25 ng/ml)
and RANKL (RL, 25 ng/ml) with various concentrations of RA
on plastic for 10 days was counted. The TRAP staining was
carried out as described in Figure 1. Each data point represents the
average 6 SD of triplicate wells. Similar results were obtained in
more than three independent experiments. *** P,0.001, com-
pared with RL group.
Found at: doi:10.1371/journal.pone.0013305.s001 (6.02 MB
TIF)
Figure S2 Expanded Figure 1C, 1F. The TRAP staining was
carried out as explained in Figure 1.
Found at: doi:10.1371/journal.pone.0013305.s002 (6.02 MB
TIF)
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